21 citations
,
March 2015 in “Journal of The American Academy of Dermatology” In this study, five out of six patients treated with vemurafenib for metastatic melanoma experienced hair loss, which improved after topical steroid treatment.
82 citations
,
March 2013 in “PLoS ONE” In this study, vemurafenib was associated with a wide range of cutaneous side effects in patients with advanced melanoma, including photosensitivity and various skin and hair changes, necessitating regular dermatological management.
4 citations
,
October 2013 in “PLoS ONE” This study found that Vemurafenib led to a broad range of cutaneous side effects in nearly all patients with advanced melanoma, highlighting the need for regular dermatologic management and UV protection.
1 citations
,
April 2022 in “JAAD case reports” In this case report, researchers observed that a 47-year-old woman developed pityriasis amiantacea after using topical minoxidil, suggesting a potential new etiology for this scalp condition.
1 citations
,
September 2023 in “Rheumatology advances in practice” This case report describes a 42-year-old woman with rheumatoid arthritis who developed extensive impetiginized pityriasis amiantacea potentially linked to her anti-TNF-α therapy with golimumab. Discontinuing the drug and other treatments led to significant clinical improvement within a month.